Rxsight, Inc. ( (RXST) ) has released its Q2 earnings. Here is a breakdown of the information Rxsight, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
RxSight, Inc. is an ophthalmic medical device company specializing in post-cataract surgery vision solutions, known for its innovative Light Adjustable Lens technology. In the second quarter of 2025, RxSight reported a revenue of $33.6 million, marking a 4% decrease from the previous year. Despite this, the company saw a 13% increase in the sale of its Light Adjustable Lenses, although sales of Light Delivery Devices fell by 49%. The company also expanded its market presence by launching its products in South Korea and Singapore and received FDA approval for expanding the dioptric power range of its lenses.
Key financial metrics revealed a gross profit of $25.2 million, up from $24.3 million the previous year, driven by a favorable product mix shift. However, operating expenses rose by 20% to $39.2 million, reflecting increased investments in sales and R&D. The company reported a net loss of $11.8 million, compared to a $6.1 million loss in the same quarter of 2024. Cash reserves slightly decreased to $227.5 million.
Looking forward, RxSight reaffirmed its 2025 guidance, projecting annual revenue between $120 million and $130 million, with a gross margin of 72% to 74%. The company plans to continue its strategic investments and commercial realignment to enhance customer engagement and expand its installed base, aiming for sustained growth in the future.